Literature DB >> 30058056

Outcomes of ICDs and CRTs in patients with chronic kidney disease: a meta-analysis of 21,000 patients.

Mohammed Shurrab1,2,3,4, Dennis T Ko5,6,7, Yazan Zayed8, Sankar D Navaneethan9, Nour Yadak10, Abeer Yaseen10, Anna Kaoutskaia6, Waad Qamhia10, Zakaria Hamdan10, Saleem Haj-Yahia10,11, Douglas S Lee5,7,12, David Newman6, Jeff S Healey13, Paula Harvey14, Eugene Crystal6,14.   

Abstract

PURPOSE: The efficacy of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT) in patients with chronic kidney disease (CKD) remains unclear. The aim of this meta-analysis is to explore the association between ICD/CRT and mortality in CKD patients.
METHODS: An electronic search was conducted using MEDLINE. We included studies that reported outcomes of interest in CKD patients stratified by the presence of ICD, CRT, or none. The primary outcome was all-cause mortality. Outcomes were pooled using random effects model. Odds ratios (OR) were reported for dichotomous variables.
RESULTS: The literature search resulted in 11 studies (observational studies) including 21,136 adult patients: seven studies compared ICD vs. no ICD and four studies compared CRT vs. ICD. All-cause mortality was significantly lower in the ICD group in comparison to that in the no ICD group (OR 0.66 (95% confidence interval [CI] 0.45; 0.98), P = 0.04). Among dialysis-only patients, all-cause mortality was significantly lower in the ICD group (OR 0.49 (95% CI 0.38; 0.64), P < 0.001). All-cause mortality was significantly lower in the CRT group in comparison to that in the ICD group (OR 0.73 (95% CI 0.57; 0.92), P = 0.01).
CONCLUSIONS: The use of ICDs is associated with lower all-cause mortality in observational studies of CKD patients. CRT use was also associated with lower all-cause mortality in CKD patients in comparison to ICDs. A randomized controlled trial is required to definitively define the role of ICDs/CRTs in CKD patients.

Entities:  

Keywords:  CRT; Chronic kidney disease; ICD; Mortality

Mesh:

Year:  2018        PMID: 30058056     DOI: 10.1007/s10840-018-0424-1

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  32 in total

1.  Cardiac Resynchronization Therapy in CKD Stage 4 Patients.

Authors:  Ulas Höke; Mand J H Khidir; Enno T van der Velde; Martin J Schalij; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-25       Impact factor: 8.237

Review 2.  Sudden cardiac death in chronic kidney disease: epidemiology and prevention.

Authors:  M Khaled Shamseddin; Patrick S Parfrey
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

3.  Renal dysfunction and clinical outcomes of patients undergoing ICD and CRTD implantation: data from the Israeli ICD registry.

Authors:  Alon Eisen; Mahmoud Suleiman; Boris Strasberg; Ron Sela; Shimon Rosenheck; Nahum A Freedberg; Michael Geist; Shlomit Ben-Zvi; Ilan Goldenberg; Michael Glikson; Moti Haim
Journal:  J Cardiovasc Electrophysiol       Date:  2014-06-06

4.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.

Authors:  Patrick H Pun; Anne S Hellkamp; Gillian D Sanders; John P Middleton; Stephen C Hammill; Hussein R Al-Khalidi; Lesley H Curtis; Gregg C Fonarow; Sana M Al-Khatib
Journal:  Nephrol Dial Transplant       Date:  2014-11-17       Impact factor: 5.992

Review 7.  Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies.

Authors:  Nader Makki; Paari Dominic Swaminathan; Janel Hanmer; Brian Olshansky
Journal:  Europace       Date:  2013-09-20       Impact factor: 5.214

8.  Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency.

Authors:  Evan C Adelstein; Alaa Shalaby; Samir Saba
Journal:  Pacing Clin Electrophysiol       Date:  2010-02-19       Impact factor: 1.976

9.  Chronic renal insufficiency is an independent predictor of mortality in implantable cardioverter-defibrillator recipients.

Authors:  Carol Chen-Scarabelli; Tiziano M Scarabelli
Journal:  Pacing Clin Electrophysiol       Date:  2007-03       Impact factor: 1.976

10.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

View more
  1 in total

1.  Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2.

Authors:  Agnieszka Gala-Błądzińska; Janusz Romanek; Danuta Mazur; Tomasz Stepek; Marcin Braun; Piotr Szafarz; Marcin Chlebuś; Andrzej Przybylski
Journal:  Cardiol Res Pract       Date:  2020-03-21       Impact factor: 1.866

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.